Dropout was a little higher than expected by 48 weeks but was higher in the placebo group than in the 30mg group as a %. Either way what is clear is the drug beat placebo in ADAS - COG and CDR SB with p values under 0.025, in brain volume reduction loss and in regards to plasma 42/40 and PTAU. Worth reminding that this was with only around 10% screening in the original enrollment, unlike Donnenamab and Lecanumab who screened out 70-80%.
Market Data 
Markets 
